Strs Ohio Has $4.02 Million Stock Holdings in Omnicell, Inc. $OMCL

Strs Ohio decreased its holdings in shares of Omnicell, Inc. (NASDAQ:OMCL) by 9.4% in the 1st quarter, according to its most recent 13F filing with the SEC. The fund owned 120,486 shares of the company’s stock after selling 12,500 shares during the period. Strs Ohio owned approximately 0.26% of Omnicell worth $4,022,000 at the end of the most recent reporting period.

A number of other large investors also recently made changes to their positions in the stock. Peregrine Capital Management LLC grew its stake in shares of Omnicell by 27.2% during the first quarter. Peregrine Capital Management LLC now owns 134,894 shares of the company’s stock worth $4,503,000 after purchasing an additional 28,835 shares during the period. Inspire Investing LLC lifted its stake in Omnicell by 54.0% in the first quarter. Inspire Investing LLC now owns 15,842 shares of the company’s stock valued at $529,000 after buying an additional 5,554 shares during the period. Louisiana State Employees Retirement System bought a new position in Omnicell during the first quarter worth about $664,000. OP Asset Management Ltd bought a new position in Omnicell during the first quarter worth about $113,000. Finally, Diversified Trust Co grew its position in shares of Omnicell by 55.7% during the 1st quarter. Diversified Trust Co now owns 12,398 shares of the company’s stock worth $414,000 after buying an additional 4,433 shares during the period. Institutional investors and hedge funds own 97.70% of the company’s stock.

Omnicell Stock Down 1.5%

Shares of NASDAQ:OMCL traded down $0.66 during trading on Tuesday, hitting $44.58. 41,273 shares of the company’s stock traded hands, compared to its average volume of 635,248. The company has a current ratio of 1.50, a quick ratio of 1.29 and a debt-to-equity ratio of 0.13. The company has a 50-day moving average price of $41.92 and a 200-day moving average price of $41.52. Omnicell, Inc. has a 52 week low of $26.84 and a 52 week high of $55.00. The company has a market cap of $2.03 billion, a price-to-earnings ratio of 100.89, a price-to-earnings-growth ratio of 1.11 and a beta of 0.96.

Omnicell (NASDAQ:OMCL) last posted its earnings results on Tuesday, April 28th. The company reported $0.55 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.33 by $0.22. Omnicell had a return on equity of 4.00% and a net margin of 1.67%.The business had revenue of $309.88 million during the quarter, compared to analysts’ expectations of $304.02 million. During the same period in the prior year, the business earned $0.26 EPS. Omnicell’s revenue for the quarter was up 14.9% compared to the same quarter last year. Omnicell has set its FY 2026 guidance at 1.800-2.000 EPS and its Q2 2026 guidance at 0.400-48.000 EPS. As a group, research analysts forecast that Omnicell, Inc. will post 1.31 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts have recently commented on OMCL shares. Zacks Research raised Omnicell from a “hold” rating to a “strong-buy” rating in a research note on Friday, May 1st. Weiss Ratings upgraded shares of Omnicell from a “sell (d)” rating to a “hold (c-)” rating in a report on Thursday, May 7th. KeyCorp upped their target price on shares of Omnicell from $60.00 to $70.00 and gave the company an “overweight” rating in a research note on Tuesday, April 28th. Benchmark reiterated a “buy” rating on shares of Omnicell in a report on Friday, March 13th. Finally, Wells Fargo & Company boosted their price target on shares of Omnicell from $52.00 to $55.00 and gave the company an “overweight” rating in a report on Thursday, April 23rd. One investment analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and one has given a Hold rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Buy” and a consensus price target of $59.86.

Insider Buying and Selling at Omnicell

In related news, EVP Nnamdi Njoku sold 3,090 shares of the business’s stock in a transaction on Monday, May 18th. The shares were sold at an average price of $43.22, for a total value of $133,549.80. Following the sale, the executive vice president directly owned 154,785 shares of the company’s stock, valued at approximately $6,689,807.70. The trade was a 1.96% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, EVP Corey J. Manley sold 5,025 shares of the company’s stock in a transaction on Monday, May 18th. The stock was sold at an average price of $43.22, for a total transaction of $217,180.50. Following the completion of the transaction, the executive vice president directly owned 112,783 shares of the company’s stock, valued at approximately $4,874,481.26. The trade was a 4.27% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 2.92% of the stock is owned by corporate insiders.

Omnicell Company Profile

Omnicell, Inc is a healthcare technology company that specializes in medication management solutions for hospitals, clinics and pharmacies. The company’s offerings encompass automated dispensing cabinets, pharmacy automation systems, IV compounding devices, and software platforms designed to optimize medication usage, streamline workflow and improve patient safety. Omnicell’s analytics and inventory management tools provide real-time visibility into medication utilization, helping healthcare providers reduce waste, manage controlled substances and ensure regulatory compliance.

Founded in Mountain View, California in 1992, Omnicell has grown through both internal innovation and strategic acquisitions to broaden its portfolio across the medication management continuum.